Co-morbidities linked to a lower risk of mortality in India compared to the UK: Study
A new study has found that known Covid-19 risk factors are not expected to have a significant impact on mortality rates in a lower-middle-income country like India, compared to a higher income country such as the UK, according to a report in ThePrint.
The study was published in BMJ journal and carried out by researchers from Stanford University, Johns Hopkins University, Dartmouth College, among others. Respiratory disease and high "uncontrolled diabetes" are risk factors that make Covid mortality worse in India, but low rates of other diseases, especially obesity, make up the difference in the UK, according to the study.
“Known Covid-19 health risk factors are not expected to have a large effect on mortality or its age distribution in India relative to England. The high share of Covid-19 deaths from people under age 60 in low and middle-income countries (LMICs) remains unexplained,” the study said. Read more here
The pandemic was a body blow to museums
The pandemic has upended millions of lives and the global economy. Among those that received a body blow in 2020 were museums. The sector was hit by massive layoffs and permanent closures. The pandemic will likely change the way museums work, according to a report in The Print.
For the first time, questions are being around about the need for brick-and-mortar museums. For instance, drive-in and drive-through exhibitions like the Toronto Van Gogh exhibition called “Gogh in Your Car” were held this year. Going forward, a building may be needed simply to store artefacts, not display them, the report said. Read more here
These states have renewed restrictions ahead of new year celebrations
Several states have tightened restrictions as a new variant of the novel coronavirus
is reported to be spreading in the UK. Here are the states that have renewed restrictions ahead of new year celebrations: Maharashtra, Tamil Nadu, Karnataka, Rajasthan, and Uttarakhand. Read the restrictions here
Lack of volunteers slows down Covaxin's phase-3 trials at Bengaluru trial site
Three drugmakers are seeking emergency-use authorisation for their Covid-19 vaccine candidates in India. One of them, Hyderabad-based Bharat Biotech, is wrestling with a less than enthusiastic participation by volunteers at its Bengaluru trial site, according to a report in The Hindu.
Lack of volunteers has slowed down phase-3 clinical trials of Bharat Biotech's Covaxin, at Vydehi Institute of Medical Sciences and Research Centre in Bengaluru. This is even as the drugmaker applied to the drug regulator a second time for emergency use authorisation on December 23, the report said. The trials are the largest phase-3 clinical trial conducted in India. It is also the only Covid-19 efficacy trial being conducted in the country to determine its suitability for a diverse Indian population. Read more here
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.